Access
To read this story in full you will need to login or make a payment (see right).
Letter
Nature 451, 73-75 (3 January 2008) | doi:10.1038/nature06446; Received 31 August 2007; Accepted 31 October 2007
Open Innovation Challenges
-
Protect Enzyme from In Planta Degradation
A proposal for stable expression of an enzyme in corn seed is desired.
-
Efficient Chromosome Doubling: Plant Cell Division
The Seeker is looking for an efficient chromosome doubling method in plants and in particular, metho...
nature jobs
Animal Science Technician
- KSR
- Cincinnati, OH, USA
Software and Computer Engineering Leader
- Life Technologies
- Carlsbad, California
Trisomy represses ApcMin-mediated tumours in mouse models of Down's syndrome
Thomas E. Sussan1,3, Annan Yang1, Fu Li2, Michael C. Ostrowski2 & Roger H. Reeves1
- Department of Physiology and The Institute for Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
- Department of Molecular and Cellular Biochemistry, Ohio State University, Columbus, Ohio 43210, USA
- Present address: Department of Environmental Health Sciences, Bloomberg School of Public Health, Baltimore, Maryland 21205, USA.
Correspondence to: Roger H. Reeves1 Correspondence and requests for materials should be addressed to R.H.R. (Email: rreeves@jhmi.edu).
Abstract
Epidemiological studies spanning more than 50 yr reach conflicting conclusions as to whether there is a lower incidence of solid tumours in people with trisomy 21 (Down's syndrome)1, 2. We used mouse models of Down's syndrome and of cancer in a biological approach to investigate the relationship between trisomy and the incidence of intestinal tumours. ApcMin-mediated tumour number was determined in aneuploid mouse models Ts65Dn, Ts1Rhr and Ms1Rhr. Trisomy for orthologues of about half of the genes on chromosome 21 (Hsa21) in Ts65Dn mice or just 33 of these genes in Ts1Rhr mice resulted in a significant reduction in the number of intestinal tumours. In Ms1Rhr, segmental monosomy for the same 33 genes that are triplicated in Ts1Rhr resulted in an increased number of tumours. Further studies demonstrated that the Ets2 gene contributed most of the dosage-sensitive effect on intestinal tumour number. The action of Ets2 as a repressor when it is overexpressed differs from tumour suppression, which requires normal gene function to prevent cellular transformation. Upregulation of Ets2 and, potentially, other genes involved in this kind of protective effect may provide a prophylactic effect in all individuals, regardless of ploidy.
- Department of Physiology and The Institute for Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
- Department of Molecular and Cellular Biochemistry, Ohio State University, Columbus, Ohio 43210, USA
- Present address: Department of Environmental Health Sciences, Bloomberg School of Public Health, Baltimore, Maryland 21205, USA.
Correspondence to: Roger H. Reeves1 Correspondence and requests for materials should be addressed to R.H.R. (Email: rreeves@jhmi.edu).
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
A mouse model for Down syndrome exhibits learning and behaviour deficitsNature Genetics Article (01 Oct 1995)
NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21Nature Article (01 Jun 2006)
Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detectionNature Medicine Technical Report (01 Feb 2007)
Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detectionNature Medicine Technical Report (01 Feb 2007)
See all 17 matches for Research
